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Background: Chronic kidney disease is strongly linked to neurocognitive deficits in adults and children, but the
pathophysiologic processes leading to these deficits remain poorly understood. The NiCK study (Neurocognitive
Assessment and Magnetic Resonance Imaging Analysis of Children and Young Adults with Chronic Kidney Disease)
seeks to address critical gaps in our understanding of the biological basis for neurologic abnormalities in chronic
kidney disease. In this report, we describe the objectives, design, and methods of the NiCK study.
Design/methods: The NiCK Study is a cross-sectional cohort study in which neurocognitive and neuroimaging
phenotyping is performed in children and young adults, aged 8 to 25 years, with chronic kidney disease compared
to healthy controls. Assessments include (1) comprehensive neurocognitive testing (using traditional and computerized
methods); (2) detailed clinical phenotyping; and (3) multimodal magnetic resonance imaging (MRI) to assess brain
structure (using T1-weighted MRI, T2-weighted MRI, and diffusion tensor imaging), functional connectivity (using
functional MRI), and blood flow (using arterial spin labeled MRI). Primary analyses will examine group differences
in neurocognitive testing and neuroimaging between subjects with chronic kidney disease and healthy controls.
Mechanisms responsible for neurocognitive dysfunction resulting from kidney disease will be explored by examining
associations between neurocognitive testing and regional changes in brain structure, functional connectivity, or blood
flow. In addition, the neurologic impact of kidney disease comorbidities such as anemia and hypertension will be
explored. We highlight aspects of our analytical approach that illustrate the challenges and opportunities posed
by data of this scope.
Discussion: The NiCK study provides a unique opportunity to address key questions about the biological basis of
neurocognitive deficits in chronic kidney disease. Understanding these mechanisms could have great public
health impact by guiding screening strategies, delivery of health information, and targeted treatment strategies
for chronic kidney disease and its related comorbidities.
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Chronic kidney disease (CKD) is strongly linked to neu-
rocognitive dysfunction in adults and children [1-4], but
the pathophysiologic processes leading to these deficits
remain poorly understood. A number of studies have
used neuroimaging to characterize the neuroanatomic
changes in children and adults with CKD. A recent sys-
tematic review [5] of such studies identified three major
types of abnormalities: (1) cerebral atrophy and cerebral
density changes; (2) signs of cerebral vascular disease;
and (3) regional blood flow changes. While the majority
of these studies were performed in adults, the small
number of pediatric studies highlighted some overlapping
findings, including cerebral atrophy and periventricular
white matter infarcts [6-10].
Although these studies have increased awareness of
neuroanatomical abnormalities in CKD, a key question
remains: What are the specific physiologic disturbances
in CKD that lead to neurocognitive changes? Potential
mechanisms include metabolic neuronal injury [11] and,
perhaps more importantly, subclinical vascular disease
[4], mediated through cardiovascular risk factors such as
anemia, dyslipidemia, and hypertension. However, it re-
mains unclear how clinical risk factors in CKD produce
specific neurophysiologic changes, and how these changes
translate to clinically relevant neurocognitive outcomes.
The Neurocognitive Assessment and Magnetic Reson-
ance Imaging Analysis of Children and Young Adults
with Chronic Kidney Disease (NiCK) Study was designed
to address this critical gap in our understanding of the
biological basis for neurologic abnormalities in CKD.
With funding from the Pennsylvania Department of Health,
this study uses a comprehensive interdisciplinary approach
and leverages unique resources at the Children’s Hospital
of Philadelphia and the University of Pennsylvania to com-
bine comprehensive neurocognitive assessments and state-
of-the-art multimodal magnetic resonance imaging (MRI)
in children and young adults with CKD.
In this report, we describe the objectives, design, and
methods of the NiCK study, and outline how the study
provides the opportunity to address key questions in the
field. We will then describe our approach to data analysis,
focusing on the challenges and opportunities posed by the
multitude of variables inherent in clinical, neurocognitive,
and neuroimaging data of this scope. Finally, we will out-
line future directions for this rich dataset, including the
potential for novel unbiased scientific discovery, and dis-
cuss the potential public health impact of this study.
Objective
The overarching objectives of the NiCK study are (1) to
determine how CKD and its associated comorbidities
affect neurocognitive function, and (2) to understand
the neurobiological basis for cognitive abnormalities inCKD. The NiCK study seeks to achieve these objectives
using the following three-pronged approach:
1. Detailed neurocognitive description of children and
young adults with CKD, along with concurrent
age-matched healthy controls, using:
a. a comprehensive battery of traditional
neurocognitive testing, and
b. a computerized neurocognitive battery
2. Detailed clinical description to explore the impact of
clinical risk factors such as hypertension and
anemia; and
3. Multimodal magnetic resonance imaging (MRI) to
identify differences in brain structure, functional
connectivity, and cerebral blood flow, using:
a. Structural MRI to explore the effects of CKD
on brain structure
b. Resting state blood oxygenation level
dependent functional MRI (BOLD fMRI) to
evaluate connectivity within brain networks that
modulate specific neurocognitive functions
c. Arterial spin labeled perfusion MRI to evaluate
global and regional cerebral blood flow.
This multifaceted approach will allow us to integrate
findings from neurocognitive testing, clinical phenotyping,
and multimodal MRI to develop a unique multi-parametric
neurocognitive phenotype for CKD. This innovative ap-
proach to assessment will provide new knowledge to
further our understanding of mechanisms underlying
neurological dysfunction in CKD.Methods/design
Study design
The NiCK study consists of a cross-sectional study of 90
pediatric and young adult subjects, aged 8 – 25 years,
with Stage 2 to 5 CKD (estimated glomerular filtration
rate [eGFR] < 90 mL/min/1.73 m2, including dialysis and
post-transplant), compared to healthy controls matched
on age and socioeconomic status (using insurance status
as a proxy).
The study was carried out in accordance with the Dec-
laration of Helsinki and was approved by the Institutional
Review Board of the Children’s Hospital of Philadelphia.
Written informed consent was obtained from all partici-
pants or their parents/legal guardians for subjects under
age 18 years.Setting
The NiCK study is performed at a large tertiary care
children’s hospital in an urban setting (the Children’s
Hospital of Philadelphia).
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Table 1 shows the inclusion and exclusion criteria for
NiCK study participants. Eligibility for CKD participants
is based on eGFR using the bedside CKiD equation [12]
for participants aged 8 to 18 years, and the Modification
of Diet in Renal Disease (MDRD) study equation [13]
for those over 18 years of age. CKD is defined as evi-
dence of kidney dysfunction for more than six months.
The lower age limit of 8 years ensures improved
compliance with imaging procedures. Since the se-
lected neurocognitive measures are standardized largely in
English, participants must have English as their primary
language. To ensure that study results reflect the effects of
kidney disease, patients with a number of comorbidities
that independently affect brain function (e.g., seizure dis-
order) or the ability to complete test measures (profound
developmental disabilities) are excluded from participating
(see Table 1).
Study procedures
The participant data collected include demographic in-
formation (age at visit, age at CKD diagnosis, gender,
maternal education, insurance status, race), past medical
history, family history, and current medications. Partici-
pants then undergo clinical, imaging, and neurocognitive
assessments as described below.
Clinical evaluations
Participants’ blood pressure (BP), heart rate, respirations,
height, weight, and body mass index are measured. La-
boratory data collected includes complete blood count,
comprehensive metabolic panel, calcium, phosphate,
cystatin C, lipid panel, and urine studies for totalTable 1 Inclusion and exclusion criteria for the NiCK study
Inclusion
criteria
Age 8 – 25 years
English is primary language for participant (most neurocog
questionnaires must be proficient in English.
CKD subjects: Stage 2–5 CKD (eGFR < 90 mL/min/1.73 m2),
Control subjects: Healthy siblings or individuals matched in
Exclusion
criteria
Conditions that would prohibit MRI: certain types of body
Auditory impairment (that cannot be corrected by a hearin
measures
History of traumatic brain injury or other significant medica
functioning (e.g. seizure disorder, genetic syndromes, syste
lupus, spina bifida, gestational age below 32 weeks, or per
Profound developmental disability or sensory-motor difficu
procedures.
A severe DSM IV-TR Axis I disorder or other psychiatric sym
the study (e.g., active psychosis)
Known drug or alcohol use within 24 hours of any assessm
Pregnancy (because of potential risk of MRI to the unborn
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate (using the b
[13] for those ≥ 18 years); DSM IV-TR, Diagnostic and Statistical Manual of Mental Diprotein, albumin, and creatinine. Urine pregnancy test-
ing is performed in post-pubertal girls prior to MRI
scanning. All participants undergo 24-hour ambulatory
blood pressure monitoring (ABPM).
Neurocognitive assessments
Traditional neurocognitive battery
A battery of age-specific neurocognitive assessments
(Table 2) is performed at the baseline visit to measure
various aspects of attention/executive functioning via
laboratory and parent/participant ratings. In addition,
age-specific depression indices and a visual analog anxiety
scale are administered. To address the potential effects of
fatigue and attention-loss on test performance, the tests
are administered in a counterbalanced format across each
study participant. A behavior coding mechanism is used
to provide examiner perception of the reliability and validity
of the test data collected.
Computerized neurocognitive battery
In addition to the traditional neurocognitive assessments
outlined in Table 2, participants also undergo a comput-
erized neurocognitive battery (CNB) developed at the
University of Pennsylvania [14]. The Penn CNB includes
14 tests assessing five neurobehavioral functions (Table 3):
executive control, episodic memory, complex cognition,
social cognition, and praxis speed. The Penn CNB assesses
both accuracy (proportion of correct responses) and speed
(response time for correct responses), with the latter vari-
able providing an additional area of exploration. The Penn
CNB requires approximately one hour to administer. Age-
specific norms for the Penn CNB are available based on
data from a large cohort (n ≈ 1800) of typically developingnitive measures standardized only in English). Parent completing
including dialysis and transplant patients
age and insurance status
metal; claustrophobia
g aid) that would significantly impede the valid collection of test
l or neurological abnormality affecting motor or higher cortical
mic diseases that can affect the brain such as sickle cell disease, cerebral
inatal injury)
lties that would preclude valid use of diagnostic instruments or scanning
ptoms that would interfere with the participant’s ability to participate in
ent
fetus).
edside CKiD equation [12] for subjects aged <18 years or the MDRD equation
sorders, 4th Edition, Text Revision; MRI, magnetic resonance imaging.
Table 2 Traditional neurocognitive and affective measurements
Domain Test name Age group for test in this
study
Intelligence Wechsler Abbreviated Scales of Intelligence (WASI) All
Attention Regulation Conners’Continuous Performance Test II (CPT-II) All
Delis-Kaplan Executive Function System Tower Subtest (D-KEFS Tower) All
Working Memory Wechsler Intelligence Scale for Children Fourth Edition Integrated (WISC-IV-I) Digit Span
Task
16 years or younger
Wechsler Intelligence Scale for Children Fourth Edition Integrated (WISC-IV-I) Spatial
Span Task
16 years or younger
Wechsler Memory Scale Third Edition (WMS-III) Digit Span Task 17 years or older
Wechsler Memory Scale Third Edition (WMS-III) Spatial Span Task 17 years or older
Executive Function
Behavior
Behavior Rating Inventory of Executive Function (BRIEF) 17 years or younger
BRIEF – Adult Version (BRIEF-A) 18 years or older
Depression Children’s Depression Inventory II Short (CDI-2 Short) 17 years or younger
Beck Depression Inventory II (BDI-II) 18 years or older
Anxiety Visual Analog Anxiety Scale All
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lopmental Cohort [15].Imaging measurements
After appropriate MRI safety screening, participants
undergo non-sedated, non-contrast MRI of the brain, ac-
quired on a Siemens Verio 3 T scanner equipped with a 32-
channel head coil. The FDA- and manufacturer-approved
sequences used are shown in Table 4. The Physiologic
Monitoring Unit (PMU) of the Siemens Verio is used to
collect pulse oxygenation data during the scan. All images
are read by board certified pediatric neuroradiologists, andTable 3 Domains and tests in the Penn computerized neuroco
Neurobehavioral function Domain
Executive Control Abstraction/mental flexibility
Attention
Working memory
Episodic Memory Verbal Memory
Facial Memory
Spatial Memory
Complex Cognition Verbal Reasoning
Nonverbal Reasoning
Spatial Processing
Social Cognition Emotion Identification
Emotion Differentiation
Age Differentiation
Praxis Speed Sensorimotor Speed
Motor Speedall clinically significant incidental findings are communi-
cated to the participants.
Structural MRI (sMRI)
An automated processing pipeline consisting of exten-
sively validated methods is applied for processing sMRI
images. The processing pipeline includes: extraction of
the brain parenchymal tissue using multi-atlas skull-
stripping [16]; inhomogeneity correction and tissue seg-
mentation into gray matter (GM), white matter (WM)
and cerebrospinal fluid (CSF) [17]; formation of regional
volumetric maps, called RAVENS (regional analysis of
volumes examined in normalized space) maps [18] usinggnitive battery
Test name Label
Penn Conditional Exclusion Test PCET
Penn Continuous Performance Test PCPT
Short Letter N-Back Test SLNB
Penn Word Memory CPW
Penn Face Memory CPF
Visual Object Learning Test VOLT
Penn Verbal Reasoning Test PVRT
Penn Matrix Reasoning Test PMAT
Penn Line Orientation Test PLOT
Penn Emotion Identification Test ER40
Penn Emotion Differentiation Test MEDF
Penn Age Differentiation Test ADT
Motor Praxis MPRAXIS
Finger Tapping Test CTAP
Table 4 Magnetic resonance imaging (MRI) Sequences performed in the NiCK study
Name Sequence parameters
3D T1 MPRAGE TR = 1.79 s, TE = 3.06 ms, TI = 1.050 s, FoV = 250 × 250 mm2, flip angle = 10°, voxel size = 1 × 1 × 1 mm3
pCASL 2D GE EPI TR = 4 s, TE = 12 ms, FoV 220 × 220 mm2, flip angle = 90°, voxel size = 3.4 × 3.4 × 5.0 mm3, labeling duration 1.5 s, postlabeling
delay 1.2 s, 40 label/control pairs
T2 FLAIR TR = 9 s, TE = 76 ms, TI = 2.5 s, FoV = 220 × 220 mm2, flip angle = 146°, voxel size = 0.9 × 0.9 × 2 mm3
T1 FLASH TR = 300 ms, TE = 2.46 ms, FoV = 225 × 225 mm2, flip angle = 60°, voxel size = 0.9 × 0.9 × 3 mm3
GRE Field Mapping TR = 499 ms, TE1 = 5.19 ms, TE2 = 7.65 ms, FoV = 192 × 192 mm2, flip angle = 60°, voxel size = 3 × 3 × 3 mm3
Resting fMRI/GE
EPI
TR = 3 s, TE 30 ms, FoV = 192 × 192 mm2, flip angle = 90°, voxel size = 3 × 3 × 3 mm3 isotropic, 102 volumes
DTI SE EPI TR = 11 s, TE = 76.4 ms, b = 0 and 1000 s/mm2, 30 directions, FoV = 256 × 256 mm2, voxel size = 2 × 2 × 2 mm3
Proton Density/T2
MRI
TR = 6.22 s, TE1= 14 ms, TE2 = 98 ms, FoV = 256 × 256 mm2, flip angle = 150°, voxel size = 1 × 1 × 2 mm3
MPRAGE, magnetization prepared rapid acquisition gradient echo; pCASL, pseudocontinuous arterial spin labeling; GE EPI, gradient-echo echo-planar imaging;
FLAIR, fluid-attenuated inversion recovery; FLASH, fast low angle shot; GRE, gradient recalled echo; fMRI, functional MRI; DTI, diffusion tensor imaging; PD, proton
density; T1, T2, weighting of applied MRI sequence; TR, repetition time; TE, echo time; TI, inversion time; FoV, field of view.
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comparative analysis of tissue volumes in the common
template space; segmentation of white matter lesions
using a multi-modal supervised learning method [20];
and segmentation into a set of expert-defined anatomic
regions of interest (ROIs) using a recently developed
multi-atlas label fusion method [21]. The segmentation
included 148 ROIs, including 98 cortical regions, white
matter regions partitioned into brain lobes, as well as
important deep structures such as hippocampus, thal-
amus and amygdala. The ROIs are organized within a
hierarchical structure such that quantitative imaging
measurements from normal and abnormal (lesion) tissues
could be calculated from different image modalities for
both individual ROIs and larger anatomical regions.
By summarizing the very high dimensional image data
with much fewer variables, calculated volumetric mea-
surements allow us to perform quantitative analyses of
regional brain volumes and fractional anisotropy, and to
evaluate the extent of brain atrophy and cerebrovascular
disease such as infarcts and leukoareosis.
Blood oxygenation level dependent functional MRI (BOLD
fMRI)
BOLD fMRI is used to evaluate connectivity within spe-
cific cognitive networks in the absence of external stimuli
(resting state BOLD fMRI). Following standard registra-
tion procedures (implemented via the program FIRST)
[22], fMRI data are registered to the standard space of the
Montreal Neurological Institute (MNI) template. Data
analysis focuses primarily on seed-based multiple re-
gression to identify differences in attention networks
(for example, the Default Mode Network, or DMN
[23]). Multiple regression follows the procedures out-
lined by Satterthwaite et al. [24], including a variety of
nuisance parameters including global fMRI signal, white
matter and CSF signal, and head motion. The resultingcorrelation (r) maps are converted to z-statistic maps (via
Fisher r-to-z transformation), which are then used as
descriptive statistics for group analyses and per-voxel
correlations with clinical and neuropsychological variables.Arterial spin labeled (ASL) MRI
ASL MRI uses spin-labeled blood water as an endogen-
ous tracer to measure regional cerebral blood flow
(CBF). This study acquired pseudocontinuous ASL [25]
sampled with 2-dimensional echoplanar imaging (EPI).
ASL images are processed using a perfusion data pro-
cessing toolbox, ASLtbx [26]. The raw EPI images are
first motion-corrected, then pairwise subtraction images
are generated from images acquired with and without
arterial labeling. The averaged difference images are used
to calculate CBF (in mL/100 g/min) as described by
Wang et al. [27]. Each subject’s data are then segmented
into GM, WM, whole-brain CBF maps that are used for
group comparisons or correlations with clinical or neu-
rocognitive indices. The ASL images are also normalized
to the standard space of the MNI brain template for
voxel-based analyses.Study size
A sample size of 90 CKD subjects and 90 healthy con-
trols was calculated based on the assumption that the
prevalence of MRI abnormalities in CKD subjects will be
12.5% and will be 1% in normal controls. This sample
size provides 80% power to detect such a difference with
95% confidence.Key questions addressed by this study
The comprehensive approach employed in the NiCK
study provides the opportunity to address some key
issues and challenges in the field.
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neurocognitive dysfunction in CKD, and does CKD affect
neurocognition independent of its vascular effects?
Vascular disease is a well-known independent risk factor
for cognitive impairment and dementia in adults [28].
Adults with CKD are at increased risk for stroke, silent
brain infarcts, white matter lesions, and dementia, pre-
sumably due to cerebral small-vessel disease [4]. How-
ever, the extent to which CKD affects neurocognition
independently of its vascular effects is unclear [29].
Discerning a CKD-specific effect is difficult in adults
due to the high prevalence of pre-existing cardiovascu-
lar disease. In contrast, children with CKD generally
have fewer pre-existing cardiovascular comorbidities.
Studying children and young adults with CKD therefore
provides the opportunity to identify neurologic changes
that may be specific to CKD.
By comparing neurocognitive test results with MRI
data, we will be able to evaluate whether specific defi-
cits correlate with changes in structure, connectivity, or
CBF in particular regions of the brain. For example, ex-
ecutive function is a domain known to be affected in
children with CKD [3]. We would therefore hypothesize
that children with deficits in executive function may have
abnormalities in the prefrontal cortex and frontotemporal
regions, such as white matter changes or volume loss on
sMRI, or regional CBF changes on ASL MRI. The impact
of level of kidney function on specific imaging parameters
can be evaluated. In addition, the effect of cardiovascular
risk factors can be analyzed, such as hypertension, anemia,
dyslipidemia, and calcium-phosphate product. Examining
these changes in children and young adults may help to
elucidate targets for early intervention.By what mechanisms do risk factors such as hypertension
contribute to neurocognitive deficits in CKD?
Hypertension has been associated with neurocognitive
dysfunction in adults [30-32] and children [33,34] with
and without CKD. Possible mechanisms include vascular
remodeling, altered cerebrovascular reactivity, or direct
neuronal effects [35-37], but there are few studies that
directly explore the neurophysiologic impact of hyper-
tension [30-32]. The NiCK study provides a unique
opportunity to address this gap in knowledge by com-
bining detailed clinical phenotyping including casual
BP measurements and ABPM, with comprehensive
neurocognitive testing and multimodal MRI. This
strategy allows us to identify specific neurocognitive
deficits caused by hypertension, and directly correlate
them with global or regional brain abnormalities such
as changes in CBF on ASL MRI, or changes in func-
tional connectivity on resting state BOLD fMRI.How does CKD affect neurocognitive function and structure
at different stages of development?
Brain maturation involves a complex series of structural
and functional changes throughout childhood, adoles-
cence, and young adulthood [38]. By studying cognitive
function and brain structure in a cross-sectional sample
of participants aged 8–25 years with and without CKD,
the NiCK study will allow us to explore how CKD and
its related comorbidities affect neurodevelopment at dif-
ferent ages. This may allow us to identify targets for
early screening or therapeutic intervention.
Approaches to data analyses and challenges
The data collected in the NiCK study provides great op-
portunities to test hypotheses regarding differences in
brain structure and function between individuals with
CKD and healthy controls. However, the heterogeneous
nature of CKD participants in this study presents both
challenges and opportunities. Their wide range of kidney
function (from dialysis-dependent up to eGFR 90 mL/
min/1.73 m2) allows us to explore neurologic changes
across the continuum of disease severity. However, this
diversity also introduces a greater number of covariates
that must be accounted for in our analyses.
Analysis of the large number of clinical and imaging
variables also presents significant challenges, particularly
in developing strategies to handle multiple comparisons.
For example, each neurocognitive testing method involves
numerous individual tasks and scores; ABPM produces
dozens of summary measures; and each MRI image
consists of millions of voxels. The analysis plan for this
study therefore includes a number of strategies for data
reduction and for comparisons of measures across vari-
ous modalities.
Clinical variables
Kidney disease severity
To determine the effect of CKD on neurocognitive func-
tion and neuroimaging parameters, our primary analytic
approach will be group comparisons between CKD and
control subjects. However, it is important to recognize
that the wide range of kidney function in the CKD group
could obscure effects of more severe kidney disease on
neurocognitive function; consequently, other measures
of CKD severity need to be considered. Further, while
eGFR would seem to be a logical marker of kidney dis-
ease severity, this study includes post-transplant subjects
and current eGFR may not account for other elements
of disease trajectory that could affect neurodevelopment.
To try to overcome this limitation, we devised a Severity
Score (Table 5) to use in our analyses. Based on an addi-
tive cumulative risk model, this score includes additional
indicators of past disease activity – whether the subject
has ever required dialysis or transplant, and whether
Table 5 Severity score system
Clinical characteristics Points
Past disease activity score
Has the subject ever received dialysis? No = 0,
Yes = 1
Has the subject ever received a kidney transplant? No = 0,
Yes = 1
Did the subject receive dialysis or transplant at age
≤ 5 years?
No = 0,
Yes = 1
Current estimated glomerular filtration rate
(eGFR, ml/min/1.73m2) score
eGFR > 60 0
30 < eGFR ≤ 60 1
15 < eGFR ≤ 30 2
eGFR ≤ 15 3
Severity Score (past disease activity score +
current eGFR score)
0 to 6
eGFR, estimated glomerular filtration rate (using the bedside CKiD equation
[12] for subjects aged <18 years or the MDRD equation [13]
for those ≥ 18 years).
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a critical developmental window. These factors are com-
bined with a score for eGFR groupings, to result in a
final Severity Score that ranges from 0 (least severe) to 6
(most severe). The Severity Score approach is simple,
and by virtue of being based on objectively determined
criteria, it is not subject to inter-rater variability. The
additional information gained by the Severity Score is
illustrated in Figure 1, which represents the clinical
course of two hypothetical subjects of the same age with
the same eGFR at the time of the study visit. Despite the
similarity in their current kidney function, it is clear thatFigure 1 Illustration of the value of the severity score.Trajectory of estimat
same age with the same eGFR at the time of the study visit. Despite the si
inflicted greater neurocognitive insult compared to that of subject A. This d
subject B vs. 2 for subject A – see Table 5), but would be missed if we onlysubject B’s trajectory has the potential to inflict greater
neurological and neurocognitive insult compared to that
of subject A – this is reflected in a higher Severity Score
(5 for subject B vs. 2 for subject A). Use of the Severity
Score in our analyses therefore allows us to include
these additional factors that could affect neurodevelop-
mental outcome, and contributes to data reduction.
Ambulatory blood pressure monitoring
There are a large number of blood pressure (BP) variables
generated by 24-hour ABPM. These include measures for
systolic and diastolic BP (SBP and DBP) and heart rate
(HR), and can be broken down into waking hours, sleep-
ing hours, and the total 24 hours. Potential variables
include mean BP, mean BP index (BP normalized for age,
height, and gender), BP load (proportion of readings
exceeding the 95th percentile for age, height, and gender),
nocturnal BP dipping (percent decrease in mean BP from
waking to sleeping), hyperbaric index (area enclosed by
the line of ambulatory BP readings above and the 95th
percentile limit line for BP readings below), and BP and
HR variability (coefficient of variation of BP readings and
HR). Many of these variables are highly correlated with
each other (e.g. mean BP and BP load); however, a growing
number of studies show that certain ABPM variables, for
example abnormal nocturnal dipping or increased BP
variability, are independent predictors of adverse cardio-
vascular and neurocognitive outcomes. Our approach in
selecting which ABPM variables to focus our analyses on
has been two-pronged: (1) review of the literature to cre-
ate an a priori list of variables expected to have the great-
est clinical significance, and (2) assessment for correlation
between ABPM variables – the variables chosen for oured glomerular filtration rate (eGFR) of two hypothetical subjects of the
milarity in their current kidney function, subject B’s course may have
ifference in clinical course is reflected in their Severity Scores (5 for
considered current eGFR.
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lated with each other, and thus potentially most inform-
ative about different aspects of BP physiology.
Neurocognitive assessments
This study includes comprehensive neurocognitive pheno-
typing in youth with CKD. Although traditional neurocog-
nitive batteries (TNB) have been used extensively in
individuals with CKD, this is the first study to utilize a com-
puterized testing (the Penn CNB) in this population. Both
the TNB and CNB provide comprehensive assessments ofTable 6 Framework for mapping tests/tasks in the traditional
neurocognitive domains
Domain Traditional neurocognitive battery (TNB) tests
Language WASI Vocabulary Subtest T-Score
WASI Similarities Subtest T-Score
Attention WMS-III Digit Span Forward Scaled Score/WISC-IV-
Scaled Score
WMS-III Spatial Span Forward Scaled Score/ WISC-
Scaled Score
CPT-II Omissions T-Score
CPT-II Variability T-Score
CPT-II Detectability T-Score
CPT-II Response Style T-Score
Inhibitory Control CPT-II Commissions T-Score
CPT-II Hit RT T-Score
Planned problem solving WASI Matrix Reasoning Subtest T Score
D-KEFS Total Achievement Scaled Score
D-KEFS Mean First-Move Time Scaled Score
Set Shifting D-KEFS Move Accuracy Ratio Scaled Score
Visual Spatial WASI Block Design Subtest T Score
WASI Matrix Reasoning Subtest T Score
Verbal Working Memory WMS-III Digit Span Backward Scaled Score/WISC-I
Scaled Score
Visual Working Memory WMS-III Spatial Span Backward Scaled Score/WISC
Backward Scaled Score
Verbal Memory WMS-III Digit Span Forward Scaled Score/WISC-IV-
Scaled Score
Visual Memory WMS-III Spatial Span Forward Scaled Score/ WISC-
Scaled Score
Ratings of Executive
Function
Global Executive Composite
Social Cognition None
Motor Speed CPT-II Hit RT T-Score
Abbreviations for TNB tests defined in Table 2, and for CNB tests in Table 3.multiple neurocognitive domains. However, since the exact
tests differ between the two batteries, one challenge we
encounter is aligning specific tasks in each battery with
neurocognitive functions tested. Table 6 demonstrates
the framework used in this study for mapping tests
within the TNB and CNB to various neurocognitive do-
mains. As the table illustrates, some neurocognitive do-
mains are tested by multiple components of the TNB
and CNB. At the same time, some tests can span sev-
eral neurocognitive domains (for example, the Penn
Verbal Reasoning Test [PVRT] assesses both languageand computerized neurocognitive batteries to specific
Computerized neurocognitive battery
(CNB) tests
Language Reasoning (PVRT)
I Digit Span Forward Attention (PCPT)
IV-I Spatial Span Forward
False Positive (i.e. incorrect) scores from:
Working Memory (SLNB)
Attention (PCPT)
Nonverbal Reasoning (PMAT)
Language Reasoning (PVRT)
Abstraction/Mental Flexibility (PCET)
Nonverbal Reasoning (PMAT)
Spatial Processing (PLOT)
V-I Digit Span Backward Working Memory (SLNB)
-IV-I Spatial Span Working Memory (SLNB)
I Digit Span Forward Verbal Memory (CPW)
IV-I Spatial Span Forward Facial Memory (CPF)
Spatial Memory (VOLT)
Abstraction/Mental Flexibility (PCET)
Emotion Identification (ER40)
Emotion Differentiation (MEDF)
Age Differentiation (ADT)
Sensorimotor Speed (MPRAXIS)
Motor Speed (CTAP)
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various tests and domains can be highly correlated, ap-
proaches such as factor analysis and principal component
analysis are required in our analyses.
Interpretation of performance across the TNB and
CNB presents another challenge. Most TNB tests measure
only accuracy, whereas most CNB tests measure both
accuracy and speed. This is potentially important, as re-
cent studies have shown that deviations from normal
brain developmental trajectories are associated with
significant deviations in performance for speed, but not
accuracy [38]. For some domains (for example, attention),
improved overall performance is reflected by better accur-
acy as well as faster speed. In contrast, in tasks that require
more complex problem-solving (for example, PVRT and
PMAT), we may see divergence in performance for accur-
acy and speed. Therefore, different analytic approaches may
be required to interpret TNB and CNB performances
across various domains. For example, for some analyses we
plan to analyze accuracy separately, but with associated
adjustments for speed.
Imaging assessments
Our primary approach for analysis of sMRI, fMRI, and
ASL MRI data in the NiCK study is to compare group
differences in pre-specified ROIs, based on anatomic
partitioning into structural/functional brain regions.
Using these pre-specified ROIs, we can explore specific
hypotheses – for example, ROIs encompassing the pre-
frontal cortex and frontotemporal areas would be hypothe-
sized to be affected by CKD, given literature describing
deficits in executive function in this population [3]. We can
therefore use the multimodal imaging approaches to com-
pare characteristics of CKD and control subjects in these
ROIs, using sMRI to detect volumetric differences, BOLD
fMRI to test for differences in functional connectivity, and
ASL MRI to compare regional CBF differences.
Whole brain approaches can also be used to explore the
global effects of specific CKD comorbidities – for example,
using ASL, we can examine the effects of hypertension and
anemia on global cerebral blood flow (CBF), or CBF within
gray matter and white matter compartments.
Additionally, a priori correlations with the neurocogni-
tive data will be explored in an effort to identify under-
lying neurological processes for manifest neurocognitive
dysfunction.
Future directions
Although the primary analyses in NiCK will be
hypothesis-driven, the nature of the imaging data collected
also provides the opportunity to explore potential new
connections and generate new hypotheses. For example,
one hypothesis-free approach to analysis of the sMRI data
uses voxel-based analysis [18,39] – this method evaluatesthe image data at its full resolution without a priori
partitioning into anatomical ROIs. This unbiased dis-
covery approach has the potential to yield new, previ-
ously unsuspected connections between regional brain
abnormalities and CKD comorbidities.
A new machine learning methodology, the brain devel-
opment index (BDI) [38], summarizes the multivariate
pattern of structural brain development using a large
sample of subjects ages 8–22, and can accurately delin-
eate trajectories of brain development. Calculating and
analyzing the BDI for NiCK subjects may potentially
help us for identification of subtle developmental abnor-
malities related to CKD.
The long-term goal of the NiCK study is to develop a
multi-parametric neuroimaging biomarker for patients
with CKD. Using machine learning and pattern recogni-
tion methods, a classification system incorporating all
the imaging measurements can be developed for individ-
ual patients. Multivariate pattern classification combining
signals from sMRI, ASL and fMRI can be performed using
the COMPARE (classification of morphological patterns
using adaptive regional elements) [40] method. This com-
bines signals from all imaging modalities to determine the
set of brain regions and measurements that jointly offer
the most distinctive set of measurements that character-
izes the brain of CKD patients. In future studies, this sort
of multi-parametric imaging index could be evaluated as a
prognostic indicator to assess whether imaging findings
can predict subsequent neurocognitive decline.
Discussion
The NiCK Study represents the most comprehensive
neurocognitive and neuroimaging phenotyping ever per-
formed in children and youth with CKD. Our innovative
approach of integrating multimodal MRI with neurocog-
nitive and clinical data provides a unique opportunity to
answer key questions in the field. These include under-
standing the independent neurologic impact of CKD, the
neurologic effects of hypertension and other cardiovascular
risk factors, and the consequences of CKD on neurodeve-
lopment from childhood through young adulthood. Under-
standing these mechanisms could have great potential
public health impact. First, this study could help to identify
improved screening strategies to identify patients at high
risk of adverse neurocognitive outcomes (for example,
determining whether neuropsychological testing or neuro-
imaging should be incorporated into clinical care of youth
with CKD). Second, neurocognitive impairment may affect
adherence to the complex medical regimens that are rou-
tinely prescribed to patients with CKD. By improving our
recognition of these deficits in our patients, we may be able
to deliver health information in a more individualized
and effective manner. Finally, by identifying mecha-
nisms through which modifiable risk factors such as
Hartung et al. BMC Nephrology  (2015) 16:66 Page 10 of 11anemia and hypertension affect neurocognition, this
study may help to guide targeted treatment strategies
to prevent future cognitive decline.
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